By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.

A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to ...

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Four Danish patients who experienced vision loss after using Novo Nordisk's Wegovy and Ozempic were awarded compensation ...

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and ...

Microdoses of weight loss drugs like Ozempic may slow down ageing and help increase longevity, a new study suggests.

The lowest doses of Ozempic and Wegovy will cost $199 per month for 2 months, and later months and other doses will cost $349 per month.